Skip to main content

Basic science research spotlight: Asmaa El-Kenawi, PharmD

headshot of Asmaa El-Kenawi on red background with lab photo behind her

Kenawi's research focuses on how cancer cells control the nutrients available in their surroundings.| Photo courtesy of IU School of Medicine

For Asmaa El-Kenawi, PharmD, her interest in what would one day become a career in cell metabolism research started early. As the child of a chemist, she enjoyed copying the chemical structures her father drew on a board in their living room. Her curiosity eventually led her to become a pharmacist. With training in pharmacology and a strong foundation in analytical chemistry, today El-Kenawi studies the distinct metabolic profile of prostate cancer.

“My first exposure to prostate cancer research came during my PhD at the Medical College of Georgia where I studied androgen receptor signaling and therapeutic resistance,” said El-Kenawi, who joined IU School of Medicine in 2023. “I was struck by how common prostate cancer is, and by the fact that some patients inevitably develop resistance to therapy, an outcome that is often fatal.”

Over time, El-Kenawi realized that studying cancer cells in isolation could not fully explain why some tumors respond to treatment and others do not. She then began exploring whether signals from the surrounding environment, including neighboring cells, could drive disease progression and drug resistance. She focused on how cancer cells control the nutrients available in their surroundings and how that in turn affects the immune cells nearby.

Funded by a $1.5 million grant from the U.S. Department of Defense, El-Kenawi’s lab at IU School of Medicine studies metabolic interactions within the prostate tumor microenvironment. Aiming to understand the pivotal roles of amino acids and cholesterol in orchestrating immune suppression, her team’s research demonstrates that alteration in these metabolic circuits can significantly contribute to therapy resistance and prostate cancer progression.

What implications does your research have for future treatment of prostate cancer?
If we can pinpoint what drives resistance, we can design combination strategies that block those escape routes from the start. We can also develop biomarkers that help clinicians choose the right therapy for each patient.

Do you have any recent findings related to your work?
African-American men are more likely to develop prostate cancer and to die from it, with biology playing a key role alongside social factors. By analyzing data from thousands of patients, we found that prostate tumors from African-American men are less able to repair DNA damage and have weakened mitochondria, the cell’s energy producers. This creates excess cellular stress and causes tumors to release molecules that suppress the immune system. These published findings reveal new targets that could lead to more effective treatments for this high-risk group.

How have IU School of Medicine and the IU Simon Comprehensive Cancer Center supported your research efforts?
Beyond funding, the biggest support has been mentorship. I received guidance from Drs. Michael Koch, Harikrishna Nakshatri, Nabil Adra and Michele Cote on grant strategy and lab management. Having access to the cancer center’s shared resources have allowed me to move quickly. The Department of Urology also encourages and supports collaboration with clinicians from different IU School of Medicine departments.

What are your plans for future research?
I plan to validate our findings in patient-derived models and secure R01-level funding. Long term, I'd like to partner with clinical colleagues in the cancer center to test our strategies in early-phase trials.

What do you find most rewarding about your work as a basic science researcher?
The most rewarding moments are mentoring students and trainees.